During the past 12 months, Bellerophon Therapeutics's average Total Assets Growth Rate was -53.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -32.10% per year.
During the past 5 years, the average Total Assets Growth Rate was -19.30% per year.
During the past 10 years, the average Total Assets Growth Rate was -15.30% per year.
During the past 11 years, Bellerophon Therapeutics's highest 3-Year average Total Assets Growth Rate was 62.40%. The lowest was -50.70%. And the median was -24.95%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Bellerophon Therapeutics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellerophon Therapeutics (OTCPK:BLPH) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Bellerophon Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Bellerophon Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Bellerophon Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLPH has been successfully added to your 